Hunter Perkins Capital Management LLC Makes New Investment in Zoetis Inc. $ZTS

Key Points

• Hunter Perkins Capital acquired 30,898 shares of Zoetis in the fourth quarter (≈$3.89M), and institutional investors now own about 92.8% of the stock.
• Zoetis beat quarterly expectations with $1.48 EPS versus $1.40 and $2.39B revenue, and set FY2026 guidance of 7.00–7.10 EPS while analysts average a 6.07 EPS forecast for the current year.
• The company declared a quarterly dividend of $0.53 (annualized $2.12, yield 1.9%), and the stock trades with a $47.9B market cap and a consensus analyst rating of "Hold."

Hunter Perkins Capital Management LLC acquired a new stake in Zoetis Inc. (NYSE:ZTS - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 30,898 shares of the company's stock, valued at approximately $3,888,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Halbert Hargrove Global Advisors LLC grew its holdings in shares of Zoetis by 496.6% during the third quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company's stock worth $25,000 after buying an additional 144 shares during the last quarter. Global Wealth Strategies & Associates purchased a new stake in Zoetis during the 4th quarter valued at approximately $25,000. KERR FINANCIAL PLANNING Corp purchased a new stake in Zoetis during the 3rd quarter valued at approximately $31,000. Holos Integrated Wealth LLC acquired a new stake in Zoetis during the 4th quarter worth approximately $32,000. Finally, Board of the Pension Protection Fund acquired a new stake in Zoetis during the 4th quarter worth approximately $38,000. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Trading Down 2.7%

Shares of ZTS stock opened at $113.48 on Friday. The stock has a market cap of $47.90 billion, a P/E ratio of 18.85, a P/E/G ratio of 1.73 and a beta of 0.95. The company has a quick ratio of 1.94, a current ratio of 3.03 and a debt-to-equity ratio of 2.71. Zoetis Inc. has a fifty-two week low of $113.29 and a fifty-two week high of $172.23. The business has a fifty day simple moving average of $123.39 and a 200-day simple moving average of $129.17.

Zoetis (NYSE:ZTS - Get Free Report) last issued its quarterly earnings data on Thursday, February 12th. The company reported $1.48 EPS for the quarter, beating analysts' consensus estimates of $1.40 by $0.08. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The firm had revenue of $2.39 billion for the quarter, compared to analysts' expectations of $2.36 billion. During the same period in the prior year, the company earned $1.40 EPS. The firm's revenue was up 3.0% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be given a $0.53 dividend. The ex-dividend date is Monday, April 20th. This represents a $2.12 annualized dividend and a dividend yield of 1.9%. Zoetis's dividend payout ratio is currently 35.22%.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on ZTS. Wall Street Zen raised Zoetis from a "hold" rating to a "buy" rating in a report on Saturday, February 21st. Weiss Ratings downgraded Zoetis from a "hold (c-)" rating to a "sell (d+)" rating in a report on Friday. UBS Group set a $136.00 price objective on shares of Zoetis in a research report on Thursday, January 29th. HSBC set a $140.00 price objective on shares of Zoetis in a research note on Wednesday, December 10th. Finally, Piper Sandler restated a "neutral" rating and issued a $135.00 target price (down from $190.00) on shares of Zoetis in a research note on Thursday, January 22nd. Six equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $152.91.

Zoetis Profile

Zoetis Inc NYSE: ZTS is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.